A Cellectis Trial Death Points To Challenges Ahead For CAR-T
Excitement over the emerging cancer immunotherapy approach has been super-charged in recent weeks, but Cellectis said it will put two trials on hold after a patient death, a problem seen with similar products.
You may also be interested in...
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
US FDA Tweaks IND Clinical Hold Policy As Number Of Holds Rises
Clinical holds by the US FDA have risen 36% since 2014.
What's New And What's Next In CAR-T After ASH
Incremental updates at the recent ASH meeting shed light on which products may follow Novartis' Kymriah and Gilead/Kite's Yescarta into the commercial market. Will it be Celgene and Bluebird or Celgene and Juno? Where do Pfizer, Servier and Cellectis stand with their off-the-shelf options?